ADCT Earnings Date & History
ADC Therapeutics SA (NEW YORK STOCK EXCHANGE, INC.) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:18 PM ET
ADC Therapeutics SA
Biotechnology
- Next earnings date
- Monday, November 9, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.22
- Revenue estimate
- $19.4M
ADCT earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $-0.22 | $-0.11 | +49.1% | $19.3M |
| Monday, May 4, 2026 | Q1 2026 | $-0.22 | $-0.13 | +40.7% | $20.9M |
| Tuesday, March 10, 2026 | Q4 2025 | $-0.27 | $-0.04 | +85.4% | $23.1M |
| Monday, November 10, 2025 | Q3 2025 | $-0.37 | $-0.30 | +18.7% | $16.4M |
| Tuesday, August 12, 2025 | Q2 2025 | $-0.48 | $-0.38 | +21.4% | $18.8M |
What the market is watching in ADCT's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next ADCT earnings date?
- ADC Therapeutics SA is scheduled to report on Monday, November 9, 2026 (Time TBD). Dates can change until the company confirms them.
- Does ADCT report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for ADCT?
- Consensus EPS for the upcoming quarter is $-0.22, on revenue of $19.4M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
ADCT earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.